Abivax


Abivax SA is a French biotechnology company headquartered in Paris, France. The company is developing treatments for patients with inflammatory diseases, viral infections and cancer.

Pipeline

ABX464 for Ulcerative Colitis

ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in a completed Phase 2a proof-of-concept study to treat lesions in ulcerative colitis. When evaluated in a Phase 2a Proof-of-Concept study, ABX464-101, ABX464 demonstrated both safety and statistically significant efficacy based on both clinical and endoscopic endpoints with 3.2-fold improvement in clinical remission rate and 4.5-fold in mucosal healing compared to placebo. Based on the positive results from the ABX464-101 study, Abivax is in the process of initiating a Phase 2b study of ABX464 in ulcerative colitis in the first quarter of 2019. The company is also conducting ABX464-102, a 12-month open-label study focusing on patients from study ABX464-101.

ABX464 for HIV

ABX464 is an oral, first-in-class, small molecule inhibiting HIV replication through an entirely new mechanism of action, and has completed three Phase 2a clinical trials. In two Phase 2a clinical trials, ABX464-004 and ABX464-005, ABX464 demonstrated up to 50% reduction of HIV-DNA in peripheral blood mononuclear cells after 28 days of combination treatment with anti-retroviral therapy.